Trademark applications and grants for Nucana P L C. Nucana P L C has 2 trademark applications. The latest application filed is for "NUTIDE"
Patent Application | Date |
---|---|
2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS 20220306675 - 17/833780 Griffith; Hugh ;   et al. | 2022-09-29 |
PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS 20220033433 - 17/323367 McGuigan (Deceased); Christopher ;   et al. | 2022-02-03 |
FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGS 20220031728 - 17/231606 Kennovin; Gordon ;   et al. | 2022-02-03 |
FORMULATION COMPRISING A GEMCITABINE-PRODRUG 20220031727 - 17/324835 Griffith; Hugh ;   et al. | 2022-02-03 |
SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS 20220024963 - 17/492301 Griffith; Hugh ;   et al. | 2022-01-27 |
Mark Image Registration | Serial | Trademark Application Date |
---|---|
"NUTIDE" 79232789 |
NUTIDE 2018-02-22 |
"NUCANA" 3373049 78928727 |
NUCANA 2006-07-13 |
SEC | 0001709626 | NuCana plc of UNITED KINGDOM |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.